Previous 10 | Next 10 |
2024-04-15 11:30:02 ET William Blair analyst issues OUTPERFORM recommendation for EXAS on April 15, 2024 10:21AM ET. The previous analyst recommendation was Outperform. EXAS was trading at $68.965 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-04-15 06:19:49 ET More on Exact Sciences Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript Exact Sciences Corporation 2023 Q4 - Results - Earnings Call Presentation Exact ...
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. ...
2024-04-11 15:05:51 ET More on Exact Sciences Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences gains after data for novel cancer screening test Exact Sciences GAAP EPS of -$0.27 beats by $0.21, revenue of $647M beats by $7.3M ...
First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test 1 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic t...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will...
2024-04-04 10:15:00 ET Cancer diagnostic specialist Exact Sciences (NASDAQ: EXAS) has lagged the market over the past three years. The pandemic and the economic troubles that followed disrupted the company's operations, and the healthcare leader remains unprofitable. However, one fa...
2024-04-04 08:43:07 ET Summary Bio-Techne is a life science tools and services company focused on the development and sale of reagents and consumables for life science research. The company's focus on the stable and lucrative life science research market has led to above-average g...
Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announce...
2024-04-02 11:58:20 ET Summary EXAS has a unique regulatory advantage as the FDA and Congress work on extending the regulatory arm over the gene diagnostics sector. Cologuard remains EXAS's growth engine going into 2024. Revaluation in the gene diagnostics sector means that EX...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...